Real-world Effectiveness of Eptinezumab in Patients in Whom ≥1 Prior Anti-CGRP Preventive Treatment had Failed: 6-month Results for an Ongoing Prospective Study
Emad Estemalik1, Stephane Regnier2, Seema Soni-Brahmbhatt2, Susanne Awad3, S. Wald Grossman2, Debra F. Eisenberg2, Damian Fiore2, Michelle Townshend4, Sandeep Sharma2, Amaal Starling5
1Cleveland Clinic Lerner College of Medicine, 2Lundbeck, 3H. Lundbeck A/S, 4ZS Associates, 5Mayo Clinic Arizona
Objective:
The INFUSE study aims to assess the real-world effectiveness of eptinezumab for preventive treatment of migraine in patients in whom ≥1 preventive calcitonin gene-related peptide antagonist (anti-CGRP) had previously failed.
Background:
The efficacy and safety of eptinezumab, an anti-CGRP monoclonal antibody administered intravenously for the preventive treatment of migraine in adults, have been demonstrated in multiple clinical trials.
Design/Methods:
The INFUSE study is an ongoing observational, prospective study with patients potentially recruited from ≥100 US infusion centers. This study includes adults with a migraine diagnosis in whom ≥1 preventive anti-CGRP (subcutaneous monoclonal antibodies and preventive oral gepants) had failed due to a lack of effectiveness or side effects and who were initiating eptinezumab treatment. Data are remotely collected on a web-based platform. The current interim analysis evaluated patient-reported outcomes through Month 6 (after 2 eptinezumab infusions), including Patient Global Impression of Change (PGIC); monthly headache days (MHDs) and 50% reduction in MHDs, both from the Migraine Disability Assessment (MIDAS); and patient-defined “good days.”
Results:
In the overall interim analysis population (female, 89% [67/75]; mean±SD age, 46.0±14.5 years), 60% (45/75) of patients reported that ≥3 anti-CGRPs had failed, with high disease burden recorded across measures at baseline. In the interim effectiveness analysis population (N=48) after 6 months of eptinezumab treatment, 71% (95% CI: 57%-82%) of patients reported any improvement (minimally, much, or very much improved). The mean MHD reduction was 5.8 days/month (P<0.001; baseline: 19.0 MHDs) on MIDAS; a MIDAS-derived ≥50% reduction in MHDs was achieved by 42% (95% CI: 29%-56%) of patients; and an increase of 5.3 good days/month was reported (P<0.001; baseline: 10.0 days/month). Results for the full study population at 6 months will be reported in the presented poster.
Conclusions:
Improvements across multiple migraine outcomes were reported after switch to eptinezumab in patients for whom prior anti-CGRP therapies have failed.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.